Neurotensin receptor 1 is a new therapeutic target for human undifferentiated pleomorphic sarcoma growth

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Undifferentiated pleomorphic sarcoma (UPS) is a common soft tissue sarcoma with limited curative treatment options for advanced disease.
• Identifying novel molecular targets is crucial for developing effective UPS therapies.
• Neurotensin receptor 1 (NTSR1), a G-protein-coupled receptor, is implicated in various cellular processes.

Purpose of the Study:

• To investigate the role of NTSR1 in UPS.
• To evaluate NTSR1 as a potential therapeutic target for UPS.
• To assess the efficacy of NTSR1 inhibition, alone and in combination with chemotherapy.

Main Methods:

• Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot analysis to assess NTSR1 expression in UPS cells.
• NTSR1 knockdown experiments to evaluate its effect on UPS cell proliferation and invasion.
• In vitro and in vivo studies using the NTSR1 inhibitor SR48692 in UPS cell lines and mouse xenograft models.
• Combination studies with standard chemotherapeutic drugs.

Main Results:

• NTSR1 expression was significantly upregulated in UPS specimens and cell lines compared to normal myoblasts.
• NTSR1 knockdown inhibited UPS cell proliferation and invasion.
• The NTSR1 inhibitor SR48692 demonstrated significant antitumor activity in UPS cells.
• SR48692 synergistically enhanced the antiproliferative effects of standard chemotherapeutic drugs.
• In vivo, SR48692 inhibited extracellular signal-regulated kinase (ERK) phosphorylation and improved the response to chemotherapy in mouse xenograft models.

Conclusions:

• NTSR1 is a promising therapeutic target for undifferentiated pleomorphic sarcoma.
• Inhibition of NTSR1 with SR48692 exhibits potent antitumor activity and enhances chemotherapy efficacy in UPS.
• SR48692 represents a potential novel therapeutic agent for targeted UPS therapy.